Bluejay Diagnostics, Inc.
No SEC Form 4 filings for $BJDX in the last 30 days.
See all $BJDX insider activity →Bluejay Diagnostics (BJDX) reported Q2 2026 results with cash and cash equivalents rising to $9.6M from $5.2M at Dec. 31, 2025, an 84% increase, driven by $7.7M net cash from financing including $7.6M from a June private placement. The company completed pivotal enrolment of 750 patients in SYMON-II to support a planned FDA 510(k) for its Symphony IL-6 test.
Bluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and said its SYMON-II pivotal study completed enrollment of 750 patients. The company is progressing toward analytical and clinical validation for a planned FDA 510(k) submission and signed a US manufacturing contract. Cash rose to about $9.6M at June 30, 2026 from $5.2M at Dec. 31, 2025, after a June private placement.
Bluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BJDX (Bluejay Diagnostics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent BJDX coverage spans market movers, corporate actions and earnings.
Stronger liquidity and progress toward an FDA 510(k) are near-term positives, but commercialization timing remains uncertain.
The update reduces clinical execution risk and pairs it with a cash runway extension, supporting a near-term path to 510(k) readiness.
Enrollment completion de-risks trial execution and supports the timeline toward clinical reporting and an FDA 510(k) submission for the Symphony IL-6 test.
The filing signals incremental insider/large-owner accumulation, but the disclosed size is modest and lacks a new fundamental catalyst.
Stock-plan amendment and related compensatory arrangements can affect future dilution/option/SAR issuance and investor perception of incentive alignment.
alphai scores every news story that mentions BJDX with an AI model for sentiment and relevance, and aggregates insider trades from Bluejay Diagnostics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bluejay Diagnostics (BJDX) reported Q2 2026 results with cash and cash equivalents rising to $9.6M from $5.2M at Dec. 31, 2025, an 84% increase, driven by $7.7M net cash from financing including $7.6M from a June private placement. The company completed pivotal enrolment of 750 patients in SYMON-II to support a planned FDA 510(k) for its Symphony IL-6 test.
5 min readBluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and said its SYMON-II pivotal study completed enrollment of 750 patients. The company is progressing toward analytical and clinical validation for a planned FDA 510(k) submission and signed a US manufacturing contract. Cash rose to about $9.6M at June 30, 2026 from $5.2M at Dec. 31, 2025, after a June private placement.
6 min readBluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.
2 min readHRT FINANCIAL LP purchased 64,047 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.51 on 2026-07-09.
2 min readBluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029420901ex10-1.htm BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO. 1 THERETO Exhibit 10.1 BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO.1 THERETO Section 1. Establishment and Purpose. 1.1 The Board of Directors (the “Boa
3 min readBluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029339001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 2, 2026, between Bluejay Diagnostics, Inc., a Delaware corporation (the “ Company ”), and e
6 min readBluejay Diagnostics (NASDAQ: BJDX) said it closed a private placement under Nasdaq rules, selling 3,655,917 shares (or pre-funded warrants) plus Series G and short-term Series H warrants at $2.325 per share. Gross proceeds were $8.5 million, with up to ~$15.2 million more if warrants are fully exercised for cash. The company expects net proceeds to fund operations into Q1 2027.
5 min readHealthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin
6 min readHealthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show
5 min readBluejay Diagnostics (NASDAQ: BJDX) said it priced a private placement under Nasdaq rules for 3,655,917 shares at $2.325 per share, with Series G and short-term Series H warrants. Gross proceeds are expected at $8.5 million, with up to ~$15.1 million more if warrants are fully exercised for cash. The company expects net proceeds to extend its cash runway into Q1 2027, supporting FDA approval and R&D.
4 min read
